Patient characteristic | Definitive treatment cohort | Total study population | |
---|---|---|---|
BLBLI (N = 24) | Carbapenem (N = 23) | N = 91 | |
Age, median [IQR], years | 77 [61–83] | 77 [68–83] | 75 [62–83] |
Female | 13 (54%) | 12 (52%) | 49 (54%) |
Hospital acquired | 7 (29%) | 4 (17%) | 20 (22%) |
Community acquired | 7 (29%) | 9 (39%) | 42 (46%) |
Healthcare associated | 10 (42%) | 10 (43%) | 29 (32%) |
CCI, median [IQR] | 2 [1-4] | 2 [1-5] | 2 [1-4] |
Pitt score, median [IQR] | 1 [0–2] | 1 [0–3] | 1 [0–2] |
APACHEII (if ICU), median [IQR] | 26 | 20 | 24 [15-28] |
ICU admission | 2 (8%) | 5 (22%) | 11 (12.1) |
E. coli | 22 (92%) | 17 (74%) | 79 (87%) |
Source: | |||
Hepato-biliary | 2 (8%) | 2 (9%) | 12 (13%) |
Urinary tract | 9 (38%) | 13 (57%) | 43 (47%) |
Neutropenic sepsis | 1 (4%) | 0 (0%) | 4 (4%) |
Other/unknown source | 12 (50%) | 8 (34%) | 32 (35%) |
Co-morbidity/devices: | |||
Moderate to severe liver disease | 3 (13%) | 1 (4%) | 7 (8%) |
Diabetes without end organ damage | 6 (25%) | 5 (22%) | 21 (23%) |
Diabetes with organ damage | 4 (17%) | 5 (22%) | 15 (17%) |
Moderate to severe renal disease | 4 (17%) | 7 (31%) | 19 (21%) |
Metastatic solid tumour | 1 (4%) | 1 (4%) | 4 (4%) |
Leukaemia or lymphoma | 1 (4%) | 2 (9%) | 7 (8%) |
Urinary device | 5 (21%) | 3 (13%) | 15 (17%) |
Immunosuppressive treatments | 2 (8%) | 4 (17%) | 12 (13%) |
Empirical therapy: | |||
3GC | 7 (29%) | 6 (26%) | 33 (36%) |
BLBLI | 11 (46%) | 5 (22%) | 25 (28%) |
Carbapenem | 0 (0%) | 2 (9%) | 8 (9%) |
Other* | 6 (25%) | 10 (43%) | 25 (27%) |
Appropriate empirical therapy | 15 (63%) | 15 (65%) | 50 (55%) |